UC San Diego researchers report that solid organ transplant recipients who were vaccinated experienced an almost 80 percent reduction in the incidence of symptomatic COVID-19 compared to unvaccinated counterparts during the same time.
Two of the leading names in health care in the tri-state region, New Jersey–based Atlantic Health System and New York–based NYU Langone Health, are teaming up to give patients greater access to heart and liver transplants and the coordinated, high-quality care needed to stay healthy. The clinical affiliation will partner NYU Langone’s nationally recognized transplant program with the nationally ranked Atlantic Health System Heart Care program located at Morristown Medical Center’s Gagnon Cardiovascular Institute (Morristown, NJ) and the ground-breaking liver services at Overlook Medical Center (Summit, NJ).
In a study published today in the Annals of Internal Medicine, Johns Hopkins Medicine researchers say they believe that, for the first time, there is evidence to show that three doses of vaccine increase antibody levels against SARS-CoV-2 — the virus that causes COVID 19 — more than the standard two-dose regimen for people who have received solid organ transplants.
In a study published today in the Journal of the American Medical Association (JAMA), Johns Hopkins Medicine researchers show that although two doses of a vaccine against SARS-CoV-2 — the virus that causes COVID 19 — confers some protection for people who have received solid organ transplants, it’s still not enough to enable them to dispense with masks, physical distancing and other safety measures.
A new study analyzes death risk from COVID-19 in organ transplant recipients and finds one treatment method greatly increased the risk.
UC San Diego Health program offers comprehensive care with excellent outcomes Nationally, more than 12,000 people need a liver transplant, including more than 2,300 Californians. Patients can wait several years on the liver transplant wait list in California before receiving…
UC San Diego Health is the first hospital on the West Coast to perform heart transplant surgery from a donor after circulatory death using a new portable organ care system. The investigational procedure could significantly decrease transplant waiting list times and improve patient outcomes.
In March 2020, Hackensack University Medical Center voluntarily inactivated its transplant list and put a hold on performing transplant surgeries due to the coronavirus (COVID-19) pandemic.
Throughout the pandemic, Hackensack University Medical Center’s organ transplant physicians continued to provide care to transplant candidates and previous organ recipients through telehealth virtual visits. Hackensack University Medical Center made the decision to reactivate its transplant list and resume offering transplant procedures now that enhanced patient safety measures designed to prevent the spread of COVID-19 have been successfully implemented across all Hackensack Meridian Health facilities.